Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Clinical Neurology,Neurology,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11060-020-03654-x.pdf
Reference31 articles.
1. Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390
2. Houillier C, Soussain C, Ghesquieres H et al (2020) Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology 94:e1027–e1039
3. Pfreundschuh M, Schubert J, Ziepert M et al (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105–116
4. Villano JL, Koshy M, Shaikh H et al (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105:1414–1418
5. Camilleri-Broet S, Criniere E, Broet P et al (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107:190–196
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Survival outcomes and treatment experience of 124 patients with primary central nervous system lymphoma;Strahlentherapie und Onkologie;2024-03-11
2. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience;Annals of Hematology;2022-11-11
3. Risk factors for high‐dose methotrexate associated toxicities in patients with primary central nervous system lymphoma;Journal of Clinical Pharmacy and Therapeutics;2022-10-19
4. Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma;Journal of Clinical Medicine;2021-09-29
5. Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome;Cancers;2021-06-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3